Literature DB >> 15261434

Prognostic factors in malignant mesothelioma.

Jacobus A Burgers1, Ronald A M Damhuis.   

Abstract

Many prognostic factors have been described in malignant mesothelioma, but only a limited number has been validated by prospective, confirmatory studies. These include performance status, histology, weight loss and leucocyte count. Their value as predictors of patient survival in malignant mesothelioma is limited, as is their role in current clinical practice. At this moment their main importance is their application in clinical studies, which allows a better delineation of the patient group to which the study results can be applied to and a more accurate comparison between different studies. The biological prognostic factors need confirmation by larger prospective trials and should be analysed with respect to the existing prognostic factors. In the future, their use might not be limited to the prediction of the patient survival but direct the development of new therapies and extend to the molecular prediction of tumour response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261434     DOI: 10.1016/j.lungcan.2004.04.012

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  3 in total

Review 1.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

2.  Prognosis and prognostic factors of patients with mesothelioma: a population-based study.

Authors:  S van der Bij; H Koffijberg; J A Burgers; P Baas; M J van de Vijver; B A J M de Mol; K G M Moons
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

3.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.